Tag Archives | ASCO

Biotech Winners 2015: Rayno Mid Caps Were Up 29.6%

Biotech Winners 2015: Rayno Mid-Cap Performance Rayno Biopharmaceutical Portfolios beat the bellwether IBB in 2015 . We previously reviewed the Rayno Small Cap Portfolio which was up 38.1% in Q4 2015  and the Mid-Caps also beat despite a big loss by Clovis Oncology after the FDA required more data on its lung cancer drug. The […]

Continue Reading 0

ASCO Rally Fades But Spec Stocks Rock: FCSC,RXDX

ASCO Week in Review- Rayno Biopharmaceutical Stocks The market action over the past week focused on speculative stocks rather than the overall biopharmaceutical sector. Major ETFs over five days were mixed with the smaller cap XBI up over 1%, the IBB flat and the FBT trailed  down 0.7%. Many of the oncology stocks with anticipated […]

Continue Reading 0

ASCO 2015 Biotech Movers Day Two: FCSC, JUNO, RXDX

Update-1 BLUE Drops 1.96% and 1.77% After Hours 6/3 In the bubbly CAR-T world bluebird bio (BLUE) and Celgene announced a deal for   for development of product candidates for B-cell maturation antigen (BMCA) utilizing bluebird bios’s gene therapy technology to modify a patient’s own T-Cells to target cancer cells. A $25M up-front payment was made but […]

Continue Reading 0

Rayno Biopharma Stocks at ASCO: ARRY, CLVS, RXDX

Biotech Indices Can’t Break Through Triple Top IBB at $365, XBI at $239 Red and green day Biotech stocks were mixed today with the major indices holding the flat line. However with all of the clinical data coming out of ASCO (American Society for Clinical Oncology) 2015 in Chicago, IL many “immuno-oncology” stocks were movers. […]

Continue Reading 0

Rayno Life Science Stocks Move Higher: CLVS, RHHBY-ASCO Preview

Rayno Biopharmaceutical Stocks– ASCO Plays or Not Large Caps Rule Clovis Oncology (CLVS) up 16.7%, 79% YTD to $100 level! Several data CLVS Presentations for ASCO including two oral and six posters for non-small cell lung cancer and ovarian cancer. Also with a valuation of only $3.4B and three platform products in the pipeline including companion […]

Continue Reading 0

Biotech Buzz Is Broken…Update 4/30…#2

Gilead (GILD) Gilead Beats Q1 Estimates: $7.4B Sales HCV , EPS $2.94, stock up 2% after hours XBI Down Another 4% Down 12.84% in Five Days Weak Tape and Sell-Off Continues…4/30…NASDAQ at 4991 XBI down 1.6% now at 2/24 lows at 212 High fliers hit with profit taking…ADRO, AGIO, JUNO, KITE etc. Large cap Celgene […]

Continue Reading 0

Biotech Bull Market: Trends to Watch in 2015… #3

Biotech Sector Moves Up In Tiny Steps Risk Remains On AACR Next Week Will Move Cancer Stocks Biotech indices and ETFs are trying to hit new highs but momentum is easing and trading is choppy. Nonetheless we are moving up from the brief correction near channel lows at the end of Q1. Sentiment remains strong. […]

Continue Reading 0

Risk Back On:Biotech Stocks Rally- IBB, XBI… Update-1…CLVS

4/13 Update  Biotech Sector Uptrend Intact XBI at 232.09 Clovis Oncology (CLVS) Up 13% On Upgrade Biotech Sector Brings In Buyers The late Q1 sell-off appears over as buyers are coming in near the 5o day moving average of the XBI, the more volatile ETF.The IBB shows a similar chart and both are up over […]

Continue Reading 0

Ignyta: Precision Medicine for Oncology Integrating Companion Diagnostics

Teva Deal Expands Portfolio and Diagnostic Capabilities Adding RXDX to Rayno Small Cap Portfolio Ignyta, Inc. (RXDX) is an emerging biopharmaceutical Company targeting new oncology drugs that inhibit Tyrosine kinase receptors (Trk) with integrated biomarker-based companion diagnostics for each product candidate. The Company has two clinical stage products in Phase 1:  RXDX-106 its lead product […]

Continue Reading 0

Snap-Back Rally In Biotech-But Lagging Other Sectors

Global Rally Today But Healthcare Sector Lags A Bit DOW up 1.49% at 17,976 NASDAQ Up 1.15% at 4947 Healthcare up 0.93% We are in Day Two of the biotech rally that was sparked last Friday with the rumor supported by a Deutsche Bank analyst that Biomarin (BMRN) was a takeover target. The Company has […]

Continue Reading 0

ASCO Oncology Stocks: Recap and Scoreboard- AGIO, MDVN, SGEN Winners

High Profile Biotechnology Companies with ASCO Presence Investors and traders waited toward the end of the ASCO Annual Meeting week to buy their favorite stocks. The biotech sector overall was boosted after the close of the meeting after a brief sell-off on June 2 and 3. Most biopharmaceutical stocks peaked in late February so ASCO […]

Continue Reading 0

Very Little Bounce in Biotech as ASCO Approaches… Update 2.. 5/22

Rally Developing-Green Screen Alert If you are underweight large cap biotech add FBT ($76.38) up 2%. Most of our large cap picks are up today: ABBV ALXN, BIIB,GILD,REGN. Reverse pattern from tuesday’s downdraft. ————– One of the worse days I have seen in small cap biotech in many months as speculation has ended and investors […]

Continue Reading 0

Pre-ASCO Watch List #2: ARIA, IMGN, PCYC

Rayno Life Science Focus Stocks: ARIA, IMGN, PCYC  Ariad (ARIA) Abstracts Several data presentations will be made for Iclusig (Ponatinib)  for leukemias and AP26113 its investigational oral inhibitor of anaplastic lymphoma kinase (ALK). A breakfast meeting featuring key investigators and slide presentations will be held on June 2. Immunogen (IMGN) Abstracts The focus will be on […]

Continue Reading 0

Pre-ASCO Movers: CLVS, INCY, PBYI

Volatility Up as ASCO Approaches The ASCO Annual Meeting is not till the end of the month but news regarding abstract titles and clinical data that will be presented at ASCO moved stocks today. Many immuno-oncology stocks have been hard hit in the 2014 sell-off as investors have moved out of small  cap speculative growth […]

Continue Reading 0

Nice Recovery Day Despite Lackluster Tape-Healthcare Lagging Sector

Global Economic Picture Not Good-Healthcare A Laggard on Rally Day Strong housing and durable goods data supported the rally today taking the S&P up 0.95% and NASDAQ up 0.82%. Comments from the China’s Central Bank helped a recovery from a free fall in the FXI at $31.70 down from the $41 level earlier this year. The […]

Continue Reading 0